Lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy | Guidance and guidelines

A list of downloadable documents created during development.

Background information

Appendix A: GE Decision paper 13 November 2010 74.29 KB

Appendix A: provisional matrix of stakeholders 05 March 2012 122.02 KB

Appendix B: proposal paper presented to the Institute's Guidance Executive 05 March 2012 147.78 KB

Multiple myeloma - lenalidomide: final appraisal determination

Multiple myeloma - lenalidomide: final appraisal determination 23 April 2009 132.06 KB

Response to consultee, commentator and public comments on the ACD and comments from website consultation

Response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD) issued October 2008 23 April 2009 153.91 KB

Response to consultee, commentator and public comments on the second Appraisal Consultation Document (ACD) issued January 2009 23 April 2009 145.07 KB

Letter from the Department of health RE: Patient Access Scheme for lenalidomide for the treatment of multiple myeloma 23 April 2009 23.63 KB

Letter from Celgene sent on 26th February 2009 23 April 2009 29.69 KB

Consultee and commentator comments on the ACD

Celgene 23 April 2009 30.95 KB

Department of Health 23 April 2009 9.55 KB

Janssen-Cilag 23 April 2009 58.65 KB

Macmillan Cancer Relief 23 April 2009 23.62 KB

Myeloma UK 23 April 2009 32.73 KB

Royal College of Nursing 23 April 2009 18 KB

Royal College of Pathologists 23 April 2009 135.45 KB

Royal College of Physicians on behalf of NCRI/RCP/RCR/ACP/JCCO 23 April 2009 34.6 KB

Sandwell PCT 23 April 2009 22.49 KB

UK Myeloma Forum and British Society for Haematology 23 April 2009 14.42 KB

Public comments on the ACD 23 April 2009 41.52 KB

Multiple myeloma - lenalidomide: appraisal consultation document 2

Multiple myeloma - lenalidomide: appraisal consultation document 2

Multiple myeloma - lenalidomide: comments on the ACD issued in October 2008

Extra analysis

Addendum to the ERG report 30 January 2009 109.98 KB

Addendum to the pre-meeting briefing: end of life - a quantitative exploration 30 January 2009 23.66 KB

Non-manufacturer comments on the ACD issued in October 2008

Department of Health 30 January 2009 6.81 KB

Janssen-Cilag 30 January 2009 50.77 KB

Macmillan Cancer Support 30 January 2009 38.58 KB

Myeloma UK, Leukaemia CARE, Leukaemia Research and the Rarer Cancers Forum 30 January 2009 66.22 KB

Royal College of Nursing 30 January 2009 18.06 KB

Royal College of Physicians, Medical Oncology Joint Special Committee 30 January 2009 21.79 KB

Royal College of Pathologist 30 January 2009 71.31 KB

Sandwell PCT 30 January 2009 15.4 KB

UK Myeloma Forum and British Society for Haematology 30 January 2009 16.79 KB

Welsh Assembly Government 30 January 2009 12.31 KB

Manufacturer comments on the ACD issued in October 2008

Celgene response to ACD 30 January 2009 101.29 KB

Celgene response to ERG lenalidomide report 30 January 2009 159.89 KB

Letter to DH regarding proposed patient access scheme 30 January 2009 138.5 KB

Response to questions from NICE on ACD comments 30 January 2009 34.31 KB

NICE letter to Celgene requesting clarification on their ACD response 30 January 2009 28.41 KB

Public comments on the ACD issued in October 2008

Letters 30 January 2009 1011.58 KB

Emails 30 January 2009 91.62 KB

Web comments 30 January 2009 773.72 KB

Letter to NICE from the Department of Health RE: Patient Access Scheme for lenalidomide for the treatment of multiple myeloma 30 January 2009 23.6 KB

Multiple myeloma - lenalidomide: appraisal consultation

Multiple myeloma - lenalidomide: appraisal consultation

Multiple myeloma - lenalidomide: evaluation report

Multiple myeloma - lenalidomide: pre-meeting briefing 28 October 2008 132.64 KB

Multiple myeloma - lenalidomide: evidence review group report 28 October 2008 996.74 KB

Non-manufacturer submissions

Myeloma UK 28 October 2008 53.98 KB

Royal College of Nursing 28 October 2008 13.66 KB

Royal College of Physicians (on behalf of the NCRI, RCP, RCR, ACP and JCCO) 28 October 2008 36.22 KB

Royal College of Pathologists 28 October 2008 124.32 KB

UK Myeloma Forum and British Society For Haematology 28 October 2008 124.69 KB

Manufacturer submission

Celgene 28 October 2008 1.44 MB

NICE request for clarification 28 October 2008 287.7 KB

Response from Celgene to request for clarification: Additional information: Part 1 28 October 2008 25.78 KB

Response from Celgene to request for clarification: Additional information: Part 2 28 October 2008 16.67 KB

Multiple myeloma - lenalidomide: Response from Celgene to request for clarification 28 October 2008 287.7 KB

Expert written personal statements

Brown 28 October 2008 58.56 KB

Cavenagh 28 October 2008 45.1 KB

Low 28 October 2008 18.39 KB

Schey 28 October 2008 41.75 KB

Multiple myeloma - lenalidomide: final scope

Multiple myeloma - lenalidomide: final scope 12 May 2008 32.17 KB

Multiple myeloma - lenalidomide: draft scope (pre-referral)

Multiple myeloma - lenalidomide: draft scope (pre-referral) 12 May 2008 33.76 KB

Multiple myeloma - lenalidomide: response to comments on the draft scope (pre-referral)

Multiple myeloma - lenalidomide: response to comments on the draft scope (pre-referral) 12 May 2008 146.67 KB

Multiple myeloma - lenalidomide: provisional matrix of consultees and commentators